Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—cefmetazole, kanamycin, and metronidazole—used together for broad-spectrum antimicrobial prophylaxis or treatment. - **Cefmetazole** is a cephamycin antibiotic (related to second-generation cephalosporins) with activity against Gram-positive, Gram-negative, and anaerobic bacteria. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins[6][8]. - **Kanamycin** is an aminoglycoside antibiotic that binds irreversibly to the 30S ribosomal subunit of bacteria, causing misreading of mRNA and inhibiting protein synthesis; it is mainly effective against aerobic Gram-negative bacteria[10]. - **Metronidazole** is a nitroimidazole antibiotic effective primarily against anaerobic bacteria and protozoa; it disrupts DNA structure in susceptible organisms leading to cell death[7]. This combination has been studied as perioperative prophylaxis in colorectal surgery (oral kanamycin + oral metronidazole preoperatively plus intravenous cefmetazole perioperatively), aiming to reduce surgical site infections by covering both aerobic and anaerobic pathogens commonly encountered in gastrointestinal procedures[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefmetazole + kanamycin + metronidazole.